Join our daily newsletter At The Bell to receive exclusive market insights
- RooLife Group (RLG) and AFT Pharmaceuticals (AFP) launch a range of over-the-counter (OTC) medicines online in China
- The medicines will be available on the Kiwi Health Global Flagship Store which launched in 2020 with an initial trial range of AFT’s health supplements
- Notably, the store has become the first New Zealand Direct to Consumer OTC online medicine marketplace in China
- Under the partnership, RooLife provides its digital marketing and store operation while AFT supplies its products which include Vitamin C&D Lipo Sachets and Kiwisoothe
- On market close, RooLife was up 20 per cent and trading at 1.2 cents while AFT was up 8.45 per cent and trading at $3.85 per share
RooLife Group (RLG) and AFT Pharmaceuticals (AFP) have launched a range of over-the-counter (OTC) medicines online in China.
The medicines will be available on the Kiwi Health Global Flagship Store which launched in 2020 with an initial trial range of AFT’s health supplements.
Following registration under China’s cross-border e-commerce (CBEC) OTC pilot scheme, the store has become the first New Zealand Direct to Consumer OTC online medicine marketplace in China.
“The Kiwi Health Global Flagship Store offers a significant growth opportunity for AFT. We are excited to be the first New Zealand company to be approved for the CBEC OTC pilot scheme that launched in 2019,” AFT Founder and Managing Director Dr Hartely Atkinson commented.
“The Kiwi Health Global Flagship Store aims to leverage the strong brand awareness of AFT’s product range, the high regard and demand for New Zealand products in China and the low numbers of OTC products approved on Tmall Global.”
Under the partnership, RooLife provides its digital marketing and store operation while AFT supplies its products which include Vitamin C&D Lipo Sachets, Ferro Sachet, Crystawash Extend and Kiwisoothe.
As part of the launch, the OTC medicine portfolio will continue to be expanded with AFT’s pain relief medication as well as a further five products.
“This partnership with AFT Pharmaceuticals places us at the forefront of the market, directly servicing the strong demand for international OTC pharmaceutical products from Chinese consumers,” RooLife Managing Director Bryan Carr said.
“This collaboration leverages our China market and e-commerce expertise, including our role of managing and achieving the necessary approvals for the sale of OTC pharmaceutical products in China, combined with AFT’s extensive pharmaceutical experience and highly regarded product range.”
On market close, RooLife was up 20 per cent and trading at 1.2 cents while AFT was up 8.45 per cent and trading at $3.85 per share.
